Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qomel CoSAU:9600 +2.08%22 EBITDA Margin % is 9.33% as of Dec. 2025, which is 53% below its 10-year median of 19.74. GuruFocus rates SAU:9600 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Qomel Co ranks better than 63.4% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qomel Co's EBITDA for the
six
months ended in Dec. 2025 was ﷼5.7 Mil. Qomel Co's Revenue for the
six
months ended in Dec. 2025 was ﷼61.0 Mil. Therefore, Qomel Co's EBITDA margin for the quarter that ended in Dec. 2025 was 9.33%.
Qomel Co (SAU:9600) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qomel Co EBITDA Margin % Related Terms
Qomel Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Qomel Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Qomel Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qomel Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qomel Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qomel Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qomel Co (SAU:9600) has a EBITDA Margin % of 9.33% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qomel Co and its competitors. This is 53% below median its historical median of 19.74. Over the past decade, Qomel Co's EBITDA Margin % has ranged from 15.62 to 21.91. According to the industry distribution chart, Qomel Co ranks #243 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 36.6%.
Is Qomel Co's EBITDA Margin % too high?
Qomel Co's current EBITDA Margin % of 9.33% is 53% below median its 10-year median of 19.74. Over the past 10 years, this metric has ranged from a low of 15.62 to a high of 21.91. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Qomel Co's value of 9.33% is 8.6% below this industry median. Based on the distribution chart, Qomel Co ranks #243 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Qomel Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Qomel Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qomel Co ranks #243 out of 664 companies for EBITDA Margin %. This puts Qomel Co in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Qomel Co's value of 9.33% is 8.6% below this benchmark. Historically, Qomel Co's own EBITDA Margin % has ranged from 15.62 to 21.91 over the past decade. While the company's 10-year median is 19.74 vs. the industry median of 10.21, Qomel Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qomel Co's current EBITDA Margin % of 9.33% is 8.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qomel Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qomel Co's current EBITDA Margin % is 9.33%, which is 53% below median its own 10-year median of 19.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qomel Co stock overvalued right now?
Qomel Co (SAU:9600) has a current EBITDA Margin % of 9.33%. The current EBITDA Margin % is 9.33%, which is 53% below median its 10-year median of 19.74 and 8.6% below the Healthcare Providers & Services industry median of 10.21. Qomel Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qomel Co (SAU:9600), the current EBITDA Margin % is 9.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qomel Co is a Saudi Arabian-based healthcare company that provides high-quality medicines and innovative medical services whose core business focuses on institutional and government supply through a professional field force and an in-depth knowledge of the local business environment They offer services such as pharmaceutical and medical supplies.
22GF Score
Get the complete analysis for SAU:9600
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9600 has been successfully added to your 
